Trial Profile
A Dual-centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Determine the Effects of Various Adjunctive Doses of Sarizotan in the Treatment of Patients With Neuroleptic-induced Tardive Dyskinesia
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sarizotan (Primary)
- Indications Drug-induced dyskinesia
- Focus Therapeutic Use
- 15 Nov 2006 New trial record.